The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 26, 2021

Filed:

May. 28, 2020
Applicants:

Regents of the University of Minnesota, Minneapolis, MN (US);

Intima Bioscience, Inc., New York, NY (US);

The U.s.a., As Represented BY the Secretary, Department of Health and Human Services, Bethesda, MD (US);

Inventors:

Branden Moriarity, Shoreview, MN (US);

Beau Webber, Coon Rapids, MN (US);

Modassir Choudhry, New York, NY (US);

Steven A. Rosenberg, Potomac, MD (US);

Douglas C. Palmer, North Bethesda, MD (US);

Nicholas P. Restifo, Chevy Chase, MD (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 35/17 (2015.01); C12N 15/113 (2010.01); C07K 14/705 (2006.01); C07K 14/47 (2006.01); A61P 31/00 (2006.01); A61P 35/00 (2006.01); A61K 9/00 (2006.01); C07K 14/725 (2006.01); C07K 14/715 (2006.01); C12N 5/0783 (2010.01); C12N 9/22 (2006.01); C12N 15/79 (2006.01); C12N 15/90 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61P 31/00 (2018.01); A61P 35/00 (2018.01); C07K 14/4703 (2013.01); C07K 14/7051 (2013.01); C07K 14/70503 (2013.01); C07K 14/70521 (2013.01); C07K 14/7158 (2013.01); C12N 5/0636 (2013.01); C12N 9/22 (2013.01); C12N 15/113 (2013.01); C12N 15/79 (2013.01); C12N 15/902 (2013.01); A61K 45/06 (2013.01); A61K 2300/00 (2013.01); C12N 2310/20 (2017.05); C12N 2510/00 (2013.01);
Abstract

Genetically modified compositions, such as non-viral vectors and tumor infiltrating lymphocytes, for the treatment of gastrointestinal cancer are disclosed. Disclosed are methods of utilizing a CRISPR system to generate genetically modified compositions. Also disclosed are the methods of making and using the genetically modified compositions for the treatment of gastrointestinal cancer.


Find Patent Forward Citations

Loading…